Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $66000.0.

  • RxSight's Asset Writedowns and Impairment fell 6024.1% to $66000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 18657.02%. This contributed to the annual value of $404000.0 for FY2024, which is 14634.15% up from last year.
  • As of Q3 2025, RxSight's Asset Writedowns and Impairment stood at $66000.0, which was down 6024.1% from $1.2 million recorded in Q2 2025.
  • RxSight's 5-year Asset Writedowns and Impairment high stood at $1.8 million for Q2 2021, and its period low was -$7000.0 during Q1 2021.
  • Its 5-year average for Asset Writedowns and Impairment is $263315.8, with a median of $71000.0 in 2024.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first crashed by 10029.94% in 2023, then soared by 1670000.0% in 2024.
  • Quarter analysis of 5 years shows RxSight's Asset Writedowns and Impairment stood at $10000.0 in 2021, then skyrocketed by 2880.0% to $298000.0 in 2022, then tumbled by 49.33% to $151000.0 in 2023, then tumbled by 52.98% to $71000.0 in 2024, then dropped by 7.04% to $66000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $66000.0 for Q3 2025, versus $1.2 million for Q2 2025 and $31000.0 for Q1 2025.